We are live on ! Find out more
FTH

Faeth Therapeutics
FTH

21 hedge funds and large institutions have $2.38M invested in Faeth Therapeutics in 2023 Q3 according to their latest regulatory filings, with funds opening new positions, 2 increasing their positions, 7 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.01% less ownership

Funds ownership: 0.59% → 0.58% (-0.01%)

13% less funds holding

Funds holding: 24 → 21 (-3)

34% less capital invested

Capital invested by funds: $3.58M → $2.38M (-$1.2M)

71% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 7

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

Holders
21
Holders Change
-3
Holders Change %
-12.5%
% of All Funds
0.33%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
2
Reduced
7
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
+$41.2K
2
Millennium Management
Millennium Management
New York
+$3.31K

Top Sellers

Rank Fund Capital Flow
1
NM
Newtyn Management
New York
-$29.3K
2
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$13.2K
3
UBS Group
UBS Group
Switzerland
-$7.42K
4
Renaissance Technologies
Renaissance Technologies
New York
-$6.12K
5
Two Sigma Advisers
Two Sigma Advisers
New York
-$5.91K
Name Holding Trade Value Shares
Change 		Change in
Stake
NM
1
Newtyn Management
New York
$1.35M -$29.3K -1,362 -1%
Vanguard Group
2
Vanguard Group
Pennsylvania
$459K – – –
Geode Capital Management
3
Geode Capital Management
Massachusetts
$102K +$41.2K +1,916 +39%
BCM
4
Bridgeway Capital Management
Texas
$84.7K – – –
DFO
5
Duquesne Family Office
New York
$80K – – –
Bank of America
6
Bank of America
North Carolina
$72.6K – – –
Renaissance Technologies
7
Renaissance Technologies
New York
$67K -$6.12K -285 -6%
Millennium Management
8
Millennium Management
New York
$43K +$3.31K +154 +6%
BlackRock
9
BlackRock
New York
$28.2K -$1.55K -72 -4%
Northern Trust
10
Northern Trust
Illinois
$20.8K – – –
State Street
11
State Street
Massachusetts
$19.3K – – –
Two Sigma Advisers
12
Two Sigma Advisers
New York
$15.5K -$5.91K -275 -22%
RJA
13
Raymond James & Associates
Florida
$11.2K – – –
DCM
14
Deuterium Capital Management
Florida
$8.8K – – –
Two Sigma Investments
15
Two Sigma Investments
New York
$8.7K -$2.9K -135 -20%
TRCT
16
Tower Research Capital (TRC)
New York
$5.81K -$236 -11 -3%
BCV
17
Banque Cantonale Vaudoise
Switzerland
$3K – – –
JP Morgan Chase
18
JP Morgan Chase
New York
$501 – – –
Morgan Stanley
19
Morgan Stanley
New York
$175 – – –
Wells Fargo
20
Wells Fargo
California
$106 – – –
Qube Research & Technologies (QRT)
21
Qube Research & Technologies (QRT)
United Kingdom
$3 – – –
HI
22
Harbour Investments
Wisconsin
$2 – – –
Dimensional Fund Advisors
23
Dimensional Fund Advisors
Texas
– -$13.2K -579 Closed
UBS Group
24
UBS Group
Switzerland
– -$7.42K -326 Closed
Royal Bank of Canada
25
Royal Bank of Canada
Ontario, Canada
– -$258 -12 -50%
1
2

FTH Hedge Fund Activity: Q3 2023 in Review

21 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Faeth Therapeutics (FTH) for Q3 2023, worth a combined $2.38M — down 34% from $3.58M a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of FTH and 0 opened new positions — a net loss of 2 holders — while 7 trimmed existing stakes and 2 added.

The largest buyer was Geode Capital Management, adding an estimated $41.2K. The largest seller was Newtyn Management, cutting an estimated $29.3K.

  • 21 institutional investors held Faeth Therapeutics (FTH) as of Q3 2023, down from 24 in Q2 2023.
  • Funds reported $2.38M of Faeth Therapeutics stock for Q3 2023, down 34% quarter-over-quarter.
  • 0 funds opened new Faeth Therapeutics positions in Q3 2023 and 2 closed out, a net change of -2 holders.
  • The largest Faeth Therapeutics buyer in Q3 2023 was Geode Capital Management, an estimated $41.2K added.
  • The largest Faeth Therapeutics seller in Q3 2023 was Newtyn Management, an estimated $29.3K sold.

Based on aggregated 13F filings for Q3 2023.